Real-world data confirmed the findings of JAVELIN Renal 101, supporting the combination of avelumab and axitinib in advanced renal cell carcinoma (RCC), said Axel Merseburger, MD, University Hospital Schleswig Holstein, Campus Lübeck, in Germany.
A real-world analysis of avelumab and axitinib to treat advanced renal cell carcinoma supports the frontline use of the combination and confirmed the findings of JAVELIN Renal 101 (NCT02684006), said Axel Merseburger, MD, professor of urology and chairman of the Department of Urology, University Hospital Schleswig Holstein, Campus Lübeck, and director of the Urologic Oncology Program, Hannover Medical School in Germany.
Merseburger presented these findings at the American Society of Clinical Oncology Genitourinary Cancers Symposium, held February 13-15, 2025, in San Francisco, California.
This transcript has been edited for clarity; captions were auto-generated.
Transcript
What was the rational for conducting the AVION study, a real-world analysis of avelumab and axitinib for renal cell carcinoma?
The rationale and the idea was we have the approval in a lot of countries for avelumab and axitinib for treating advanced and metastatic renal cell carcinoma, and we wanted to have a look at if this trial data, which was published and shown at several conferences, would stand also in real-world data in countries like Russia, Greece, and Germany that were the countries included in the AVION trial.
Were there any notable differences in outcomes or adverse events between the real-world study and what was seen in JAVELIN Renal 101?
Now, fortunately not, and this was really real life in European and even Russian sites that recruited the patients. Some of them haven't had any access to further subsequent treatment, which probably resulted also in this overall survival, similar to JAVELIN Renal 101.1
I think no, there's not a big difference, and the real-world data supports what we have found in the pivotal trial.
The observation period was 24 months. Is there a need for a longer follow-up period and what might it tell us or confirm?
Yes, we will do the follow-up. We will continue to do the follow-up and hope to report maybe at next year's ASCO GU 2026. Also, the publication plan is there. And once we have had more follow-up data, it's going to be published in a journal. We don't know where yet, but it's going to be definitely published.
Reference
Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103-1115. doi:10.1056/NEJMoa1816047
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More